(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged 96-week results, asciminib, ASH Annual Meeting, chronic myeloid leukemia, CML care, discontinuation rate, imatinib, major molecular response, MMR, National Comprehensive Cancer Network, NCCN, newly diagnosed settings, Novartis, oncology, Ph+ CML-CP, Phase II ASC2ESCALATE trial, Phase III ASC4FIRST trial, Philadelphia chromosome-positive chronic myeloid leukemia, safety, Scemblix, Second-Line Treatment, severe adverse events, standard-of-care, TKIs, tolerability, tyrosine kinase inhibitors
ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec[1] Data demonstrated higher rates of early and deeper molecular response in newly diagnosed patients, including MR4.5, and a reduced … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Giuseppe Saglio, Glivec®, imatinib, leukemia, nilotinib, Novartis, Novartis's Tasigna®, Ph+ CML, Phase III studies
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?